Vertex Pharmaceuticals (MA) Announces Presentation of New Data From Hepatitis C Development Program at American Association for Study of Liver Diseases Annual Meeting

Published: Oct 01, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its hepatitis C research and development program will be presented at The Liver Meeting®, the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, November 9 to 13, 2012. Presentations will include data on INCIVEK® (telaprevir) tablets, Vertex’s approved medicine for the treatment of genotype 1 chronic hepatitis C, and two of the company’s hepatitis C treatments in development: VX-222, a non-nucleoside polymerase inhibitor, and ALS-2200 (VX-135), a uridine nucleotide analogue pro-drug.

Back to news